SG Americas Securities LLC Sells 7,022 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

SG Americas Securities LLC reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 86.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,062 shares of the company’s stock after selling 7,022 shares during the period. SG Americas Securities LLC’s holdings in Neurocrine Biosciences were worth $145,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Brooklyn Investment Group grew its stake in Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 115 shares during the last quarter. Blue Trust Inc. raised its stake in Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of Neurocrine Biosciences by 211.6% during the 4th quarter. UMB Bank n.a. now owns 455 shares of the company’s stock worth $62,000 after acquiring an additional 309 shares during the period. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Neurocrine Biosciences by 42.0% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock worth $72,000 after purchasing an additional 157 shares during the period. Finally, Truvestments Capital LLC purchased a new position in shares of Neurocrine Biosciences during the third quarter worth $63,000. 92.59% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on NBIX. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research report on Friday. Bank of America dropped their target price on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a report on Friday. UBS Group boosted their price objective on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Friday. Finally, Piper Sandler reissued an “overweight” rating and issued a $160.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $168.35.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, CFO Matt Abernethy sold 1,283 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.87, for a total value of $196,132.21. Following the completion of the sale, the chief financial officer now owns 32,681 shares in the company, valued at $4,995,944.47. This represents a 3.78 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the transaction, the chief executive officer now owns 135,392 shares in the company, valued at approximately $19,157,968. This represents a 32.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 222,693 shares of company stock valued at $32,718,279 over the last three months. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $118.81 on Tuesday. The company has a market capitalization of $12.03 billion, a P/E ratio of 36.11 and a beta of 0.33. The company’s 50 day simple moving average is $138.81 and its 200 day simple moving average is $131.42. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. On average, analysts anticipate that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.